Skip to main content

Medtronic Inc(MDT-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

U.S. Patent Office rejects Axonics' latest challenge to Medtronic patents

Newswire.ca - Thu Mar 21, 1:51PM CDT

Medtronic moves for patent infringement litigation to resume

DUBLIN, March 21, 2024  /CNW/ -- Medtronic (NYSE:MDT), the global leader in healthcare technology, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has affirmed the validity of claims in two of its patents in an ongoing patent infringement lawsuit filed by Medtronic against Axonics over sacral neuromodulation (SNM) technologies. Cumulatively, the PTAB has now upheld the validity of five of the Medtronic patents at issue in this lawsuit.

Read more at newswire.ca

Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe